ReviewAdvances in experimental medicine and biology2020
Immune-Related Adverse Events: Pneumonitis.
Review in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06688422 (Incentive Spirometry for Respiratory Enhancement Pilot Clinical Trial in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy), which is not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Incentive Spirometry for Respiratory Enhancement Pilot Clinical Trial in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Clinical efficacy of immunotherapy in combination of locoregional therapies for advanced hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- A Systematic Review of Mechanisms, Incidence, and Management of Trastuzumab Deruxtecan Induced ILD/Pneumonitis in Solid Tumors.Drug design, development and therapy · 2025Pooled it
- miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Machine learning for identifying risk factors of nosocomial infection in cancer patients with immune checkpoint inhibitor-related pneumonia.BMC infectious diseases · 2026Article
- Enlargement of a Preexisting Pulmonary Nodule Mimicking Metastasis during Neoadjuvant Chemotherapy with Pembrolizumab for Triple-Negative Breast Cancer.Surgical case reports · 2026Article
- Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling.Journal for immunotherapy of cancer · 2025Article
- [Research Progress of Anti-lung Cancer Drug-related Interstitial Lung Disease].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.International journal of molecular sciences · 2024Review
- Meta-analysis of Censored Adverse Events.The New England Journal of Statistics in Data Science · 2024Article
- Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.NPJ precision oncology · 2024Article
- Optimizing Inpatient Care for Lung Cancer Patients with Immune Checkpoint Inhibitor- Related Pneumonitis Using a Clinical Care Pathway Algorithm.Research square · 2024Article
- Toxicity in the era of immune checkpoint inhibitor therapy.Frontiers in immunology · 2024Review
- Dynamic immune signatures of patients with advanced non-small-cell lung cancer for infection prediction after immunotherapy.Frontiers in immunology · 2024Article
- A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment.Cureus · 2023Article
- Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging.Neoplasia (New York, N.Y.) · 2023Article
- Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning.Frontiers in immunology · 2023Article
- [Immune-related pneumonitis: A differential diagnosis of SARS-CoV-2 pneumonia].Revue des maladies respiratoires · 2022Article
- Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?Discover oncology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Checkpoint inhibitors are part of the family of immunotherapies and are increasingly being used in a wide variety of cancers. Immune-related adverse events pose a major challenge in the treatment of cancer patients. Pneumonitis is a rare immune-related adverse event that presents in distinct patterns. The goal of this chapter is to instruct readers on the incidence and clinical manifestations of pneumonitis and to offer guidance in the evaluation and treatment of patients with pneumonitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.